Why 'Liquid Cartilage' causes confusion — and what it actually means

Search for 'liquid cartilage injection' and the results will pull in two genuinely different things — which is not a minor quirk of the internet but a reflection of how the phrase has evolved clinically. For years, 'liquid cartilage' has circulated as patient shorthand for hyaluronic acid (HA) gel shots, the viscosupplementation injections that top up synovial fluid to ease joint friction. Millions of people have had them, and the nickname stuck.

Then ChondroFiller arrived in UK clinics and trademarked 'Liquid Cartilage™' as its brand name — a product that is mechanistically unrelated to HA. The result is a genuine split in search intent: someone typing that phrase may be researching straightforward lubricating gel, or they may be looking at a collagen scaffold implant designed to recruit the body's own repair cells. The distinction carries real clinical weight for anyone choosing between them.

The clearest single line in this comparison: HA lubricates the joint; ChondroFiller scaffolds it. That is not an incremental difference — it is a difference in what each treatment is fundamentally trying to do. The sections below cover both options on their own terms.

What hyaluronic acid injections do for the knee

Hyaluronic acid is a naturally occurring molecule in synovial fluid, and viscosupplementation works by replenishing it — restoring the joint's lubricating properties when that fluid has thinned or degraded. In plain terms, an HA injection makes the joint move more easily and with less pain by reducing friction between the articulating surfaces. It does not alter the cartilage itself.

Relief typically lasts three to six months, after which a repeat course is usually needed to maintain the effect. This cycle — injection, improvement, wear-off, re-injection — is the expected pattern rather than an exception. For patients with broad, diffuse osteoarthritis affecting the whole joint surface, that palliative cycle can be a reasonable management strategy: reducing pain allows for better function and exercise, which supports joint health over time.

Guideline bodies are, however, measured in their enthusiasm. The American College of Rheumatology and the American Academy of Orthopaedic Surgeons offer only conditional or negative recommendations for HA viscosupplementation, reflecting inconsistent results across randomised controlled trials. OARSI takes a slightly more supportive line, offering conditional endorsement. The variation in molecular weight across HA products — from low-weight single injections to high-weight multi-injection courses such as hylan G-F 20 — may partly explain that inconsistency, though no KB source definitively resolves the debate.

What HA does not address is a discrete, focal cartilage lesion — a defined area of damage rather than general joint wear. Lubricating the whole joint cannot fill or scaffold a specific defect, and this is the clinical gap that ChondroFiller is designed for.

How ChondroFiller works — scaffold, not lubricant

Unlike HA, ChondroFiller is not a lubricant at all — it is a CE-marked Class III medical device: an acellular scaffold made from murine-derived Type I collagen, regulated and implanted as a medical implant rather than administered as a drug or supplement.

In practice, the treatment is delivered as an ultrasound-guided outpatient injection into the focal cartilage defect. Once in place, the liquid collagen gels within approximately three to five minutes, forming a dimensionally stable three-dimensional matrix that sits within the lesion. The scaffold then works through a process called acellular matrix-induced chondrogenesis — in patient-facing terms, the framework encourages the body's own progenitor cells to migrate in from the surrounding synovium and subchondral bone and begin repair activity. No donor cells are introduced; the repair potential comes entirely from the patient.

Direct mechanistic evidence for this cell migration comes from a 2025 ex vivo study that measured a 2.4-fold increase in DNA content within the scaffold by day 14 — a meaningful signal that cells are moving into the matrix and establishing themselves, not simply sitting alongside it.

Over one to two years the scaffold is progressively resorbed, ideally replaced by the body's own repair tissue. Published clinical data in the knee show International Knee Documentation Committee (IKDC) scores improving by approximately 30 points over 12 months across multiple evaluations. It is worth noting that these studies have been primarily manufacturer-sponsored; the mechanistic rationale is well-supported, but the independent trial base is thinner than the body of randomised evidence that exists for HA viscosupplementation. ChondroFiller's repair claims are scientifically plausible — they should not, however, be read as definitively proven by large-scale independent RCTs at this stage.

Focal defect vs diffuse arthritis — which patients suit each treatment

The single most important clinical question is not which injection is better — it is what type of cartilage problem is actually present.

ChondroFiller is designed for a discrete, focal cartilage defect: a defined area of damage, typically resulting from injury or a localised wear pattern, where the surrounding cartilage is relatively intact. The scaffold works by filling that specific lesion; it cannot address the diffuse, whole-joint degeneration characteristic of osteoarthritis, where the damage is spread across multiple surfaces with no clear boundary.

HA viscosupplementation, by contrast, works across the whole joint. For patients whose primary problem is general joint-wide wear — reduced synovial fluid, diffuse surface roughening, chronic stiffness — the palliative lubrication HA provides is a more appropriate fit than a targeted scaffold placed into a lesion that does not clearly exist.

Neither treatment is appropriate for end-stage bone-on-bone arthritis, where the cartilage layer has been lost entirely and joint replacement becomes the relevant conversation.

The complication is that presentations are not always clean. Some patients have background osteoarthritis alongside a focal defect, and deciding which problem to prioritise — and whether the focal defect is actually the primary driver of symptoms — requires careful assessment. MRI typically provides the most informative picture: it can characterise defect depth, size, and location in a way that clinical examination alone cannot.

This is why a consultant-led imaging review is the necessary first step before either pathway is considered. A plausible treatment choice made without that characterisation risks treating the wrong problem.

Practical differences — procedure, course length, and cost

On the day of treatment, the practical experience of receiving either injection is broadly similar: both are delivered as ultrasound-guided outpatient procedures, typically completed within an hour, with no theatre admission, no general anaesthetic, and no surgical incisions.

The differences emerge in what follows.

HA viscosupplementation is usually given as a short course — commonly one to three injections — and because its effect is symptomatic rather than structural, the benefit gradually fades. Patients who find it helpful generally return for repeat courses on a recurring basis, making it an ongoing maintenance commitment rather than a one-off procedure.

ChondroFiller is designed as a single course. Because the scaffold recruits the patient's own cells and is progressively replaced by repair tissue, published data suggest benefit that can extend over several years without the need for repeat cycles. That single-course structure is a clinically meaningful consideration for any patient weighing a recurring treatment commitment against a front-loaded intervention.

Operator skill is a more consequential variable with ChondroFiller than with standard HA. Accurate placement of the collagen scaffold within a defined focal lesion under ultrasound guidance demands a higher degree of clinical expertise; this is a specialist procedure, not a commodity one, and the outcome is more sensitive to precise image-guided delivery.

On cost, ChondroFiller is substantially more expensive than HA viscosupplementation. The guide cost varies with lesion size and the number of boxes required, and patients should request current pricing directly from the treating clinic. Neither treatment is currently funded by the NHS. Cost is one practical factor in shared decision-making, but it should be weighed alongside the difference in treatment duration and the biological goals of each approach — not treated as a reason to choose or avoid either option in isolation.

Getting the right assessment before choosing

Two questions, answered in the right order, determine which pathway makes clinical sense. First: is the cartilage damage focal and discrete, or spread diffusely across the joint? Second: is the treatment goal symptomatic palliation — managing friction and stiffness over time — or structural support of a defined defect through scaffold-induced repair? A treatment choice made before those questions are resolved risks addressing the wrong problem.

Arriving at those answers requires imaging, not just symptoms. MRI can characterise defect depth, boundary, and surface area in ways that clinical examination alone cannot — and it is precisely that characterisation that separates a patient likely to benefit from a collagen scaffold from one better suited to viscosupplementation. A clinician at any practice should be able to walk through this reasoning explicitly before recommending either route.

MSK Doctors consultants carry out this kind of structured assessment at clinics in Sleaford, Lincolnshire (NG34) — where an Open MRI scanner and the Regeneration Hub sit on site — and in Grantham (NG31). Appointments are available without a GP referral and without NHS-style waiting lists. To arrange an assessment, visit mskdoctors.com.

1. [1] Kartogenin-encapsulated self-healing injectable hydrogel based on hyaluronic acid for viscosupplementation in knee osteoarthritis. (2025). https://doi.org/10.1016/j.ijbiomac.2025.147304 https://doi.org/10.1016/j.ijbiomac.2025.147304